XTX Topco Ltd Makes New Investment in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

XTX Topco Ltd acquired a new stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 112,713 shares of the company’s stock, valued at approximately $246,000. XTX Topco Ltd owned 0.16% of Ventyx Biosciences at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Palumbo Wealth Management LLC acquired a new position in Ventyx Biosciences in the third quarter valued at approximately $26,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Ventyx Biosciences by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock valued at $30,000 after acquiring an additional 5,310 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Ventyx Biosciences during the 2nd quarter valued at $32,000. Intech Investment Management LLC bought a new position in Ventyx Biosciences during the third quarter worth $42,000. Finally, The Manufacturers Life Insurance Company grew its holdings in Ventyx Biosciences by 41.1% in the second quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock worth $56,000 after purchasing an additional 7,096 shares during the period. Institutional investors own 97.88% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on VTYX. HC Wainwright reissued a “neutral” rating and set a $6.00 price objective on shares of Ventyx Biosciences in a research report on Monday, November 11th. Oppenheimer reissued an “outperform” rating and issued a $9.00 price objective (down previously from $10.00) on shares of Ventyx Biosciences in a research note on Friday, November 8th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Ventyx Biosciences Price Performance

VTYX opened at $2.30 on Thursday. The firm has a market capitalization of $162.64 million, a PE ratio of -0.97 and a beta of 0.48. Ventyx Biosciences, Inc. has a fifty-two week low of $1.67 and a fifty-two week high of $11.48. The company’s 50-day moving average is $2.30 and its 200 day moving average is $2.40.

Insider Transactions at Ventyx Biosciences

In related news, CEO Raju Mohan purchased 238,248 shares of the firm’s stock in a transaction that occurred on Friday, November 22nd. The stock was acquired at an average price of $1.83 per share, for a total transaction of $435,993.84. Following the completion of the acquisition, the chief executive officer now owns 1,913,276 shares of the company’s stock, valued at $3,501,295.08. This represents a 14.22 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 18.18% of the company’s stock.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.